MedPath

Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Recruiting
Conditions
Lung Adenocarcinoma
Interventions
Procedure: Lobectomy with systemic lymph node dissection
Procedure: Segmentectomy with systemic lymph node dissection
Registration Number
NCT05838053
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Brief Summary

This study aims to evaluate the superiority in recurrence-free survival of lobectomy compared with segmentectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype positive by intraoperative frozen sections.

Detailed Description

At present, the technology of intraoperative frozen section has gradually matured, which can diagnose the benign and malignant tumors and guide the resection strategy for peripheral small-sized lung adenocarcinoma. Travis et al. reported high specificity of intraoperative frozen section in the identification of micropapillary components, confirming that intraoperative frozen section may guide the selection of surgical procedures. However, there is still little evidence whether segmentectomy is appropriate for invasive adenocarcinoma without micropapillary patterns. This prospective and multi-center study was aimed to evaluate the superiority in recurrence free survival and overall survival of lobectomy compared with segmentectomy in patients with lung adenocarcinoma (≤ 2 cm) containing positive micropapillary components.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
446
Inclusion Criteria
  • Tumor size ≤ 2 cm;
  • Solitary tumor and located in the outer third of the lung field;
  • Preoperative CT indicated that the nodules were single nodules or Concomitant nodules was less than minimal invasive adenocarcinoma;
  • Intraoperative frozen section confirmed invasive lung adenocarcinoma and with micropapillary and solid patterns positive (>5%);
  • Confirmation of R0 status by intraoperative frozen section analysis;
  • Pulmonary function could withstand both segmentectomy and lobectomy (FEV1 > 1.5 L or FEV1% ≥ 60%);
  • Sufficient organ function;
  • Performance status of 0,1 or 2;
  • Written informed consent.
Exclusion Criteria
  • The tumor is close to the hilum, which cannot perform segmentectomy ;
  • Patients suspected of lymph node positive by preoperative examination, including CT scans and mediastinal lymph node biopsy;
  • Evidence revealed locally advanced or metastatic disease;
  • Intraoperative exploration revealed accidental pleural dissemination.
  • Patients with severe damage to heart, liver and kidney function (grade 3 ~ 4, Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) over 3 times the normal upper limit, Cr over the normal upper limit).
  • Patients concomitant with other malignant tumors;
  • Patients had prior chemotherapy, radiotherapy or molecular targeted therapy for this malignancy.
  • History of severe heart disease, heart failure, myocardial infarction within the past 6 months.
  • The patients who were not suitable for inclusion by researchers' evaluation.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Lobectomy with systemic lymph node dissectionLobectomy with systemic lymph node dissectionlobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.
Segmentectomy with systemic lymph node dissectionSegmentectomy with systemic lymph node dissectionSegmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation. As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy.
Primary Outcome Measures
NameTimeMethod
recurrence-free survival rate5 year

Recurrence-free survival (RFS) was defined as the time from surgery until recurrence or death from any cause

Secondary Outcome Measures
NameTimeMethod
overall survival rate5 year

Overall survival (OS) was defined as the time from surgery until death from any cause

Trial Locations

Locations (1)

Shanghai Pulmonary Hospital

🇨🇳

Yangpu, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath